ArticleJournal of the American Heart Association2025
Specific Cardiovascular Mortality in Cancer Survivors: A Nationwide Population-Based Cohort Study in Japan.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Temporal Trends in Cause-Specific Cardiovascular Disease Mortality Following Cancer Diagnosis.Cancer medicine · 2026Article
- A systematic review of artificial intelligence in radiotherapy associated cardiovascular toxicity.Cardio-oncology (London, England) · 2026Review
- Cardiovascular-kidney-metabolic syndrome and risk of all-cause and cause-specific mortality among cancer survivors: a population-based cohort study.Clinical epigenetics · 2026Article
- Heartbreakers and healers: RNA rebels in cardio-oncology.Seminars in cancer biology · 2026Review
- Association of the C-reactive protein-triglyceride-glucose index with the risk of incident cardiovascular disease in rectal cancer survivors.Frontiers in cardiovascular medicine · 2026Article
- Tissue factor activity and 1-year mortality in patients with active cancer and acute ischemic stroke: findings from the SCAN study.Research and practice in thrombosis and haemostasis · 2026Article
- Association between cancer and cardiovascular disease risk: a cross-sectional study of 241,064 individuals.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImprovements in cancer survivorship have led to concern about cardiovascular disease (CVD) among cancer survivors. This study aimed to investigate CVD mortality in patients with cancer compared with the general population, with a focus on specific CVDs including ischemic heart disease, heart failure, aortic dissection, ischemic stroke, and hemorrhagic stroke.
methodsThis nationwide population-based cohort study used data from the National Cancer Registry in Japan. Patients diagnosed with cancer between January 2016 and December 2019 were included. Standardized mortality ratios (SMRs) and their 95% CIs were calculated to compare the risk of CVD mortality between patients with cancer and the general population. The SMRs were also computed for each specific CVD.
resultsThe study included 3 972 603 patients, representing 6 212 672 person-years of follow-up. Patients with cancer had a 2.39-fold higher risk of cardiovascular death compared with the general population. The SMR was highest for nonlymphoid hematologic malignancies (4.32 [95% CI, 4.15-4.50]). The mortality risk varied across specific types of CVD. Nonlymphoid hematologic malignancies had the highest SMRs for ischemic heart disease (3.15 [95% CI, 2.87-3.45]) and heart failure (7.65 [95% CI, 7.07-8.27]). The SMR for aortic dissection, ischemic stroke, and hemorrhagic stroke were highest for laryngeal (3.31 [95% CI, 2.29-4.79]), pancreatic (5.39 [95% CI, 4.79-6.05]), and liver (3.75 [95% CI, 3.36-4.18]) cancers, respectively.
conclusionsPatients with cancer had a higher CVD mortality risk, which was prominent in nonlymphoid hematologic malignancies. The mortality risk varied considerably by cancer type and specific CVD type.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.